Autolus Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL), a commercial-stage biopharmaceutical company focused on programmed T cell therapies, has announced its participation in two upcoming investor conferences in Miami, FL.
The company will attend the Jefferies Biotech on the Beach Summit on March 11, 2025, where management will host investor meetings. Additionally, CEO Dr. Christian Itin will deliver a fireside chat presentation at the Leerink Global Biopharma Conference on March 12, 2025, at 8:40am EDT / 12:40pm GMT.
A webcast of the fireside chat will be accessible through the company's website's 'Events' page, with a replay available for 90 days post-presentation.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
In the trading session that priced this news, AUTL gained 12.57%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences.
Jefferies Biotech on the Beach Summit
Management to host investor meetings
Date: March 11, 2025
Location: Miami, FL
Leerink Global Biopharma Conference
Fireside Chat Presentation
Date and time: March 12, 2025; 8:40am EDT / 12:40pm GMT
Location: Miami, FL
Presenter: Chief Executive Officer Dr. Christian Itin
A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
Olivia Manser
+44 7780 471 568
o.manser@autolus.com
